Since its inception in 1999, Galapagos has used warrant plans to
incentivize
personnel and management and have them share in the success of the
company.
Following warrant exercises during the exercise period from 9 June 2012
through
22 June 2012, Galapagos issued 18,699 new ordinary shares on 29 June 2012
for a
total capital increase (including issuance premium) of EUR160,253.07. No
member
of the Board or Executive Committee exercised warrants.

To date, Galapagos' total share capital amounts to EUR143,770,414.14;
the total
number of securities conferring voting rights is 26,577,554, which is
also the
total number of voting rights (the "denominator"), and all securities
conferring
voting rights and all voting rights are of the same category. The total
number
of rights (warrants) to subscribe to not yet issued securities conferring
voting
rights is 3,171,362, which equals the total number of voting rights
that may
result from the exercise of these warrants. Galapagos does not
have any
convertible bonds or shares without voting rights outstanding.

About Galapagos
Galapagos (EURONEXT BRUSSELS: GLPG) (PINKSHEETS: GLPYY) is a mid-size
biotechnology company
specialized in the discovery and development of small molecule and
antibody
therapies with novel modes-of-action. The Company is progressing
GLPG0634, as
well as one of the largest pipelines in biotech, with four
programs in
development and over 30 discovery programs. The Galapagos Group has about
800
employees and operates facilities in six countries, with global
headquarters in
Mechelen, Belgium. More info at: www.glpg.com

This release may contain forward-looking statements, including,
without
limitation, statements containing the words "believes,"
"anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will,"
"could,"
"stands to," and "continues," as well as similar expressions. Such
forward-looking statements may involve known and unknown risks,
uncertainties and other
factors which might cause the actual results, financial condition,
performance
or achievements of Galapagos, or industry results, to be materially
different
from any historic or future results, financial conditions,
performance or
achievements expressed or implied by such forward-looking statements.
Given
these uncertainties, the reader is advised not to place any undue
reliance on
such forward-looking statements. These forward-looking statements speak
only as
of the date of publication of this document. Galapagos expressly
disclaims any
obligation to update any such forward-looking statements in this
document to
reflect any change in its expectations with regard thereto or any
change in
events, conditions or circumstances on which any such statement is based,
unless
required by law or regulation.

This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and
other applicable laws; and

(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.